AICentralResources
AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
BenevolentAI vs Recursion Pharmaceuticals

VS
BenevolentAI official logo and brand icon

BenevolentAI

Enterprise
Visit WebsiteFull Review
Recursion Pharmaceuticals official logo and brand icon

Recursion Pharmaceuticals

Enterprise
Visit WebsiteFull Review

Verdict by Category

Detailed category analysis is not available for this comparison.
View BenevolentAI View Recursion Pharmaceuticals
Feature & Spec Matrix

Detailed Comparison23 Criteria

Complete side-by-side breakdown of specifications, capabilities, and feature parity

Swipe horizontally to compare features
Feature / Spec
BenevolentAI
BenevolentAI
Recursion Pharmaceuticals
Recursion Pharmaceuticals
Pricing Model
EnterpriseBenevolentAI operates through enterprise pharma collaboration agreements and platform licensing — there is no self-serve access or published pricing. Revenue models include: discovery collaborations with pharma companies (AstraZeneca, Merck) structured as multi-year agreements with upfront fees and milestones; licensing of its knowledge exploration tools as standalone software to pharma R&D organizations; and advancing its own clinical pipeline to inflection points for licensing or co-development. Total funding raised is approximately $1.9B, with the company listed on Euronext Amsterdam (AMS: BAI). Contact BenevolentAI through benevolent.com for partnership and platform licensing inquiries.
EnterpriseAI-enabled drug discovery and mapping (Recursion OS) — Custom biopharma enterprise partnership agreements only
Starting Price
Custom / Contact Sales
Custom / Contact Sales
Free Plan & Trial Scope
Difference
No free access — enterprise pharma partnerships and platform licensing via sales team
No self-serve access — enterprise pharma collaborations and data licensing via partnership team
User Rating Score
Unrated
Unrated
Ideal Workflow / Use Case
Difference
Pharmaceutical companies and researchers needing AI-powered knowledge mining for novel drug target identification and disease hypothesis generation in complex diseases
Major pharma companies and researchers needing AI-powered biology mapping, target discovery, and drug candidate generation at industrial scale through the Recursion OS platform
Enterprise & Scalability
Difference
Euronext Amsterdam listed (AMS: BAI), $1.9B total raised, in-house wet lab facilities in Cambridge UK, strategic collaborations with AstraZeneca and Merck, HIPAA/GDPR compliant data practices, enterprise licensing for knowledge exploration tools
NASDAQ listed (RXRX), $500M+ in pharma partnership milestones earned, enterprise collaboration agreements with Roche/Genentech and Sanofi, automated biology and chemistry labs at industrial scale in Salt Lake City and Oxford, and data licensing for external researchers
Core Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Benevolent Platform — AI knowledge graph integrating scientific literature, databases, and experimental data
Supported
Supported
Target identification and disease hypothesis generation from multimodal biomedical data
Supported
Supported
In-house wet lab facilities in Cambridge UK for AI hypothesis validation
Difference
BenevolentAI Advantage
Not listed
Clinical pipeline: BEN-8744 (Phase 1, ulcerative colitis), BEN-28010 (preclinical, glioblastoma), BEN-34712 (preclinical, ALS)
Difference
BenevolentAI Advantage
Not listed
Strategic collaborations with AstraZeneca and Merck for AI-powered drug target discovery
Supported
Supported
Knowledge exploration tools for pharma partners — licensed separately from drug pipeline
Supported
Supported
Integrated AI + wet lab model: AI generates hypotheses, scientists validate in physical experiments
Difference
BenevolentAI Advantage
Not listed
Multi-disease focus: oncology, rare disease, fibrosis, CNS, immunology, and cardiovascular
Difference
BenevolentAI Advantage
Not listed
Listed on Euronext Amsterdam (AMS: BAI) — $1.9B total raised since founding in 2013
Difference
BenevolentAI Advantage
Not listed
Offices in London HQ, Cambridge wet labs, and New York
Difference
BenevolentAI Advantage
Not listed
REC-4881 for FAP — 53% polyp reduction in Phase 2, FDA registration discussions begun 2026
Difference
Not listed
Recursion Pharmaceuticals Advantage
REC-1245 (RBM39 degrader) in Phase 1/2 DAHLIA study for solid tumors
Difference
Not listed
Recursion Pharmaceuticals Advantage
REC-4539 (LSD1 inhibitor) — first patient dosed in Phase 1 ENLYGHT study 2026
Difference
Not listed
Recursion Pharmaceuticals Advantage
Sanofi partnership — $134M earned to date across 5 milestones
Difference
Not listed
Recursion Pharmaceuticals Advantage
$500M+ in cumulative pharma partnership milestones earned to date
Difference
Not listed
Recursion Pharmaceuticals Advantage
NASDAQ: RXRX — founded 2013; $74.7M revenue in 2025; acquired Exscientia in 2024
Difference
Not listed
Recursion Pharmaceuticals Advantage
BenevolentAI icon

BenevolentAI Pros & Cons

Pros

  • Fully integrated AI + wet lab model — unique among AI drug discovery platforms
  • AstraZeneca and Merck partnerships validate the platform's target identification quality
  • In-house wet labs in Cambridge close the loop between AI prediction and biology
  • Euronext Amsterdam listed (AMS: BAI) — $1.9B raised, publicly accountable
  • Phase 1 clinical data for BEN-8744 (ulcerative colitis) represents real clinical progress
  • Multiple disease areas covered: oncology, rare disease, CNS, fibrosis, and immunology
  • Knowledge exploration tools can be licensed separately from drug pipeline

Cons

  • Listed on Euronext Amsterdam (AMS: BAI) — less accessible to US retail investors
  • Clinical pipeline still in early stages — no approved drugs yet
  • Smaller than competitors like Recursion in terms of funding and team size
  • Revenue dependent on collaboration milestones — lumpy and uncertain
  • Wet-lab operations add cost complexity vs. pure software drug discovery peers
Recursion Pharmaceuticals icon

Recursion Pharmaceuticals Pros & Cons

Pros

  • $500M+ in pharma partnership milestones — most validated AI drug platform by commercial revenue
  • Recursion OS is the most vertically integrated AI drug discovery system — biology to clinic in one platform
  • Industrial-scale automated labs generate data no other company can replicate
  • Phase 2 FAP clinical proof of concept — 53% polyp reduction — FDA registration discussions began
  • Roche/Genentech and Sanofi as partners — two of the world's top 5 pharma companies
  • Exscientia acquisition in 2024 added cutting-edge small molecule AI design capabilities
  • Cash runway guided into early 2028 — disciplined capital allocation

Cons

  • Stock (RXRX) is below $5 — significant market skepticism on timeline to commercial drugs
  • Operating cash burn of ~$390M in 2026 — needs continued capital or milestone payments
  • Acquired Exscientia in 2024 — integration complexity and added operational overhead
  • No approved drugs yet — clinical proof of concept still early stage
  • Proprietary platform requires industrial-scale automation infrastructure that can't be self-built
Head-to-Head Battle Cards

Popular Comparisons

Direct feature matrices, pricing breakdowns, and real-world benchmark duels

All AI Healthcare Tools comparisons
Recursion Pharmaceuticals vs Insilico Medicine Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Recursion Pharmaceuticals and Insilico Medicine in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
BenevolentAI vs Freed AI Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between BenevolentAI and Freed AI in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Recursion Pharmaceuticals vs Suki AI Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Recursion Pharmaceuticals and Suki AI in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Infermedica vs BenevolentAI Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Infermedica and BenevolentAI in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare